Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 223,742
  • Shares Outstanding, K 14,788
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,180 K
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.99
Trade MACK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.03 on 05/15/24
  • Next Earnings Date 05/16/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.67 +3.14%
on 04/18/24
15.16 -0.23%
on 05/17/24
+0.45 (+3.07%)
since 04/17/24
3-Month
14.60 +3.63%
on 03/12/24
15.16 -0.23%
on 05/17/24
+0.43 (+2.93%)
since 02/16/24
52-Week
11.53 +31.22%
on 07/19/23
15.89 -4.78%
on 02/13/24
+2.31 (+18.02%)
since 05/17/23

Most Recent Stories

More News
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 225.01 (+0.47%)
NYT : 55.29 (+0.36%)
ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
MACK : 15.13 (unch)
INCY : 65.80 (+0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 85.50 (-0.67%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.42 (unch)
ONCY : 1.0200 (unch)
MACK : 15.13 (unch)
INCY : 65.80 (+0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 85.50 (-0.67%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

AAPL : 225.01 (+0.47%)
ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
MACK : 15.13 (unch)
INCY : 65.80 (+0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 85.50 (-0.67%)
Merrimack Reports First Quarter 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

MACK : 15.13 (unch)
Merrimack Reports Full Year 2022 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.

MACK : 15.13 (unch)
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...

MACK : 15.13 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 333.24 (-0.81%)
MACK : 15.13 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 333.24 (-0.81%)
MACK : 15.13 (unch)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

ONCY : 1.0200 (unch)
ONC.TO : 1.42 (unch)
MACK : 15.13 (unch)
NRBO : 4.35 (+0.23%)
MRK : 124.38 (-1.04%)
RNAZ : 0.3035 (-61.70%)
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The pancreatic cancer treatment market is fiercely competitive. To maintain the escalating market...

ONC.TO : 1.42 (unch)
ONCY : 1.0200 (unch)
MACK : 15.13 (unch)
NRBO : 4.35 (+0.23%)
MRK : 124.38 (-1.04%)
RNAZ : 0.3035 (-61.70%)

Business Summary

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 15.19
2nd Resistance Point 15.18
1st Resistance Point 15.15
Last Price 15.13
1st Support Level 15.12
2nd Support Level 15.11
3rd Support Level 15.08

See More

52-Week High 15.89
Last Price 15.13
Fibonacci 61.8% 14.22
Fibonacci 50% 13.71
Fibonacci 38.2% 13.20
52-Week Low 11.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar